and systemic mast cell disease (SMCD) . 3 In systemic mastocytosis, an exchange from an aspartate to a valine at position 816 can be identified in the majority of cases.
3 Imatinib (Glivec, STI571) is a tyrosine kinase inhibitor capable of inhibiting mutant cKit and thus induces responses in patients with GIST 4 and cKit-positive AML.
5 Unfortunately, imatinib is not active in mast cell disease, since the D816V activating cKit mutation is located within the activation loop and causes a strong resistance to imatinib by virtue of a structural change at the entrance of the enzymatic pocket.
6 AMN107 is a novel tyrosine kinase inhibitor displaying promising activity in patients with imatinib-resistant chronic and advanced-phase CML. 7 In cKit activating mutations other than cKit D816V such as cKit K642E or cKit del560À561 , AMN107 displays equipotent activity to imatinib. 8 We therefore aimed to determine whether AMN107 might be useful in the treatment of systemic mastocytosis. We examined the effect of AMN107 on Ba/F3 cells, which were transformed with murine cKit harbouring cKit D814V corresponding to human cKit D816V . As shown in Figure 1 , imatinib did not inhibit cell proliferation in Ba/F3 cKit D814V cells as expected. In contrast, AMN107 effectively suppressed the growth of Ba/F3 cKit D814V cells at inhibitor concentrations of 1-2 mM (Figure 1 ). Similar results were obtained with Ba/F3 cells expressing the human cKit D816V mutant. We then examined whether treatment of cKit D814V cells with AMN107 gives rise to apoptotic cell death. AMN107 initiated apoptosis in cKit D814V cells with 83 and 96 per cent Annexin V-positive cells after 48 hours of culture in the presence of 2 and 4 mM AMN107, respectively (Figure 2) .
We conclude that AMN107 constitutes a promising candidate for the treatment of systemic mastocytosis, a disease which is typically driven by the imatinib-resistant, activating cKit mutation D816V. Chronic myelogenous leukemia (CML), a clonal hematopoietic stem cell disorder, is characterized by the presence of the BCR-ABL tyrosine kinase (TK) oncogene, the product of Philadelphia (Ph) chromosome that results from a t(9;22)(q34; q11) reciprocal translocation. Imatinib mesylate (Glivec, STI571) inhibits BCR-ABL TK activity and induces specifically leukemic cell apoptosis. This drug has proved very successful for the treatment of CML when administered in the chronic phase. In contrast, in the advanced phase, remissions are less frequent and are followed by the emergence of resistance to imatinib. BCR-ABL gene amplification and mutations in the BCR-ABL kinase domain are the most frequent mechanisms of resistance.
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Mutations causing amino-acid substitution can be classified into four groups: (i) in the imatinib binding site-like T315I mutation, (ii) in the P-loop (ATP phosphate binding loop for ATP) like G250E mutation, (iii) in the activation loop, and (iv) in the C-terminal lobe of the enzyme. [1] [2] [3] In the current study, we investigated a new mutation in the P-loop domain G250A detected in a resistant patient. An in vitro functional study was performed using G250A mutant compared to a G250E mutant already characterized and to one of the most resistant mutant T315I engineered in Baf/BCR-ABL cells.
Previously, 18 patients in late chronic phase CML and resistant to imatinib mesylate after a median time of 13 months of treatment were investigated to screen for mutations in the TK domain. For these patients, resistance was defined by the absence of cytogenetic response after 6 months of treatment, whatever the hematological response. Briefly, after extraction of total RNA from peripheral blood samples, a seminested reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to amplify a 1298-bp fragment including the BCR-ABL fusion point and the ATP binding site and was followed by direct sequencing. The mutation was considered as detected only if the same mutation was detected in repeat analysis. A new G250A (substitution of a glycine by an alanine) mutation was identified in our patient's group. The patient was a 57-year-old woman diagnosed in 1987 with Ph-positive CML in chronic phase (Sokal ¼ 0.68). She underwent leukapheresis and was treated with interferon (IFN). Neither cytogenetic response nor hematological remission was achieved and evolution to accelerated phase was rapid, so she was treated by double autologous peripheral blood stem cell transplantation ( To evaluate the role of this substitution on the imatinib resistance of leukemic cells, we generated three different plasmids by site-directed mutagenesis: a wild-type (wt) BCR-ABL, a G250A mutation and a G250E mutation, from the 9.5 kb plasmid pEYK3.1 containing the complete BCR-ABL sequence with the T315I mutation (kindly provided by G Daley 2 ). Baf/ BCR-ABL cells were transfected with the different mutants, named Baf/BCR-ABL wt, Baf/BCR-ABL T315I, Baf/BCR-ABL G250E and Baf/BCR-ABL G250A, and tested for imatinib sensitivity with increasing doses of imatinib (0, 0.1, 0.5, 1, 5 and 10 mM). The viability test demonstrated that G250A nucleotide substitution conferred resistance to imatinib because 88% of cells were still alive after 4 days with 0.5 mM of imatinib. However, this resistance was moderate because 70% of cells were dead after 4 days with 1 mM of imatinib. For the Baf/BCR-ABL wt, 59% of cells were alive after 4 days with 0.5 mM of imatinib and 67% of cells were dead with 1 mM. In contrast, the Baf/BCR-ABL T315I and G250E cells were resistant to the inhibitor. Indeed, 96% of cells were still alive after 4 days of treatment with 1 mM of imatinib (data not shown). Cellular
